{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:48:48Z","timestamp":1792900128345,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hereditary Hemorrhagic Telangiectasia (HHT) is a rare inherited disorder characterized by development of mucocutaneous telangiectases and visceral organ arteriovenous malformations, which can lead to recurrent, spontaneous bleeding and development of iron deficiency anemia. The primary objective of this study was to ascertain the relationship between epistaxis severity scores (ESS), laboratory values, genotype, and phenotype in HHT. Our secondary objective was to assess efficacy of systemic antifibrinolytic therapy in reducing ESS in HHT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodology<\/jats:title>\n                <jats:p>We conducted a retrospective review of patients seen at the UNC HHT Center from January 1, 2009 to February 28, 2015. ESS, demographics, and results of genetic testing were abstracted from the medical record. Response to antifibrinolytic therapy was evaluated by comparing pre-post ESS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One hundred and forty nine patients were eligible with 116 having genetic testing and 33 without. Age, hemoglobin and ferritin levels were predictive of ESS. Of the 116 patients that underwent genetic testing: 63 had an <jats:italic>ACVRL1<\/jats:italic> mutation, 40 had an <jats:italic>ENG<\/jats:italic> mutation, 2 had a <jats:italic>SMAD4<\/jats:italic> mutation, and 11 patients had no pathologic HHT genetic variation detected. Compared to patients without a detectable HHT-associated genetic variation, patients with a HHT-associated genetic variation had higher ESS scores (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Neither ESS nor genotype was predictive of pulmonary or brain AVMs. Twenty-four HHT patients with ESS\u2009&gt;\u20094 were started on antifibrinolytic therapy (tranexamic acid or aminocaproic acid) and had a post-treatment ESS recorded. All patients had a decrease in ESS of &gt;\u20090.71 (minimal meaningful difference), but patients taking antifibrinolytics displayed larger decreases. No patients on antifibrinolytics experienced a VTE with median follow up of 13\u2009months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We demonstrate that the ESS correlates with age, hemoglobin and ferritin. Additionally, we demonstrate that HHT patients with genetic mutations have higher ESS scores. Our data demonstrate that antifibrinolytics are effective in decreasing epistaxis severity and safe with long-term use in HHT patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-01453-1","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T11:04:10Z","timestamp":1594638250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding"],"prefix":"10.1186","volume":"15","author":[{"given":"Joan D.","family":"Beckman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quefeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Hester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofri","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6672-3082","authenticated-orcid":false,"given":"Raj S.","family":"Kasthuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"issue":"2","key":"1453_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/jmg.2009.069013","volume":"48","author":"ME Faughnan","year":"2011","unstructured":"Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48(2):73\u201387.","journal-title":"J Med Genet"},{"issue":"1","key":"1453_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-weber syndrome). Am J Med Genet. 2000;91(1):66\u20137.","journal-title":"Am J Med Genet"},{"issue":"7","key":"1453_CR3","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/GIM.0b013e3182136d32","volume":"13","author":"J McDonald","year":"2011","unstructured":"McDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med. 2011;13(7):607\u201316.","journal-title":"Genet Med"},{"issue":"1","key":"1453_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3121\/cmr.4.1.66","volume":"4","author":"LA Fernandez","year":"2006","unstructured":"Fernandez LA, Sanz-Rodriguez F, Blanco FJ, Bernabeu C, Botella LM. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway. Clin Med Res. 2006;4(1):66\u201378.","journal-title":"Clin Med Res"},{"issue":"9412","key":"1453_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0140-6736(04)15732-2","volume":"363","author":"CJ Gallione","year":"2004","unstructured":"Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, Mitchell G, Drouin E, Westermann CJ, Marchuk DA. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004;363(9412):852\u20139.","journal-title":"Lancet"},{"issue":"1","key":"1453_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/GIM.0b013e31802d8373","volume":"9","author":"G Lesca","year":"2007","unstructured":"Lesca G, Olivieri C, Burnichon N, Pagella F, Carette MF, Gilbert-Dussardier B, Goizet C, Roume J, Rabilloud M, Saurin JC, et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med. 2007;9(1):14\u201322.","journal-title":"Genet Med"},{"key":"1453_CR7","doi-asserted-by":"crossref","unstructured":"McDonald J, Wooderchak-Donahue W, VanSant WC, Whitehead K, Stevenson DA, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet. 2015;6:1.","DOI":"10.3389\/fgene.2015.00001"},{"key":"1453_CR8","doi-asserted-by":"crossref","unstructured":"Kasthuri RS, Montifar M, Nelson J, Kim H, Lawton MT, Faughnan ME. Brain Vascular Malformation Consortium HHTIG: Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia. Am J Hematol. 2017;92(10). First published: 22 June 2017.","DOI":"10.1002\/ajh.24832"},{"issue":"2","key":"1453_CR9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4193\/Rhino09.138","volume":"49","author":"I Ingrand","year":"2011","unstructured":"Ingrand I, Ingrand P, Gilbert-Dussardier B, Defossez G, Jouhet V, Migeot V, Dufour X, Klossek JM. Altered quality of life in Rendu-Osler-weber disease related to recurrent epistaxis. Rhinology. 2011;49(2):155\u201362.","journal-title":"Rhinology"},{"issue":"11","key":"1453_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/alr.21374","volume":"4","author":"CA Merlo","year":"2014","unstructured":"Merlo CA, Yin LX, Hoag JB, Mitchell SE, Reh DD. The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol. 2014;4(11):921\u20135.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"1453_CR11","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/lary.20818","volume":"120","author":"JB Hoag","year":"2010","unstructured":"Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope. 2010;120(4):838\u201343.","journal-title":"Laryngoscope"},{"issue":"5","key":"1453_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/lary.25669","volume":"126","author":"LX Yin","year":"2016","unstructured":"Yin LX, Reh DD, Hoag JB, Mitchell SE, Mathai SC, Robinson GM, Merlo CA. The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia. Laryngoscope. 2016;126(5):1029\u201332.","journal-title":"Laryngoscope"},{"issue":"8","key":"1453_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/jmg.40.8.585","volume":"40","author":"J Berg","year":"2003","unstructured":"Berg J, Porteous M, Reinhardt D, Gallione C, Holloway S, Umasunthar T, Lux A, McKinnon W, Marchuk D, Guttmacher A. Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations. J Med Genet. 2003;40(8):585\u201390.","journal-title":"J Med Genet"},{"issue":"6","key":"1453_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/j.1538-7836.2007.02531.x","volume":"5","author":"C Sabba","year":"2007","unstructured":"Sabba C, Pasculli G, Lenato GM, Suppressa P, Lastella P, Memeo M, Dicuonzo F, Guant G. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost. 2007;5(6):1149\u201357.","journal-title":"J Thromb Haemost"},{"issue":"21","key":"1453_CR15","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/ajmg.a.32243","volume":"146A","author":"TG Letteboer","year":"2008","unstructured":"Letteboer TG, Mager HJ, Snijder RJ, Lindhout D. Ploos van Amstel HK, Zanen P, Westermann KJ: genotype-phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet A. 2008;146A(21):2733\u20139.","journal-title":"Am J Med Genet A"},{"issue":"5","key":"1453_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2500\/ajra.2012.26.3809","volume":"26","author":"SL Richer","year":"2012","unstructured":"Richer SL, Geisthoff UW, Livada N, Ward PD, Johnson L, Mainka A, Henderson KJ, Maune S, White RI Jr, Ross DA. The Young's procedure for severe epistaxis from hereditary hemorrhagic telangiectasia. Am J Rhinol Allergy. 2012;26(5):401\u20134.","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"1453_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/MOO.0000000000000319","volume":"25","author":"MD Lupa","year":"2017","unstructured":"Lupa MD, Wise SK. Comprehensive management of hereditary hemorrhagic telangiectasia. Curr Opin Otolaryngol Head Neck Surg. 2017;25(1):64\u20138.","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"6","key":"1453_CR18","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/alr.22094","volume":"8","author":"AA Halderman","year":"2018","unstructured":"Halderman AA, Ryan MW, Clark C, Sindwani R, Reh DD, Poetker DM, Invernizzi R, Marple BF. Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. Int Forum Allergy Rhinol. 2018;8(6):713\u201328.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"1453_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/archinte.161.5.767","volume":"161","author":"A Klepfish","year":"2001","unstructured":"Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia. Arch Intern Med. 2001;161(5):767.","journal-title":"Arch Intern Med"},{"issue":"9","key":"1453_CR20","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/jth.12654","volume":"12","author":"S Gaillard","year":"2014","unstructured":"Gaillard S, Dupuis-Girod S, Boutitie F, Riviere S, Moriniere S, Hatron PY, Manfredi G, Kaminsky P, Capitaine AL, Roy P, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12(9):1494\u2013502.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1453_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","volume":"134","author":"UW Geisthoff","year":"2014","unstructured":"Geisthoff UW, Seyfert UT, Kubler M, Bieg B, Plinkert PK, Konig J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014;134(3):565\u201371.","journal-title":"Thromb Res"},{"issue":"9","key":"1453_CR22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jama.2016.11387","volume":"316","author":"S Dupuis-Girod","year":"2016","unstructured":"Dupuis-Girod S, Ambrun A, Decullier E, Fargeton AE, Roux A, Breant V, Colombet B, Riviere S, Cartier C, Lacombe P, et al. Effect of Bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic Telangectasia: a randomized clinical trial. JAMA. 2016;316(9):934\u201342.","journal-title":"JAMA"},{"issue":"9","key":"1453_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jama.2016.11724","volume":"316","author":"KJ Whitehead","year":"2016","unstructured":"Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH, James M, Everett EM, Clancy MS, Faughnan ME, et al. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA. 2016;316(9):943\u201351.","journal-title":"JAMA"},{"issue":"2","key":"1453_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1160\/TH06-07-0373","volume":"97","author":"LA Fernandez","year":"2007","unstructured":"Fernandez LA, Garrido-Martin EM, Sanz-Rodriguez F, Ramirez JR, Morales-Angulo C, Zarrabeitia R, Perez-Molino A, Bernabeu C, Botella LM. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1\/endoglin pathway in endothelial cells. Thromb Haemost. 2007;97(2):254\u201362.","journal-title":"Thromb Haemost"},{"issue":"1","key":"1453_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00277-014-2169-y","volume":"94","author":"N Zaffar","year":"2015","unstructured":"Zaffar N, Ravichakaravarthy T, Faughnan ME, Shehata N. The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey. Ann Hematol. 2015;94(1):145\u201352.","journal-title":"Ann Hematol"},{"issue":"3","key":"1453_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ajmg.1320320302","volume":"32","author":"H Plauchu","year":"1989","unstructured":"Plauchu H, de Chadarevian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet. 1989;32(3):291\u20137.","journal-title":"Am J Med Genet"},{"key":"1453_CR27","doi-asserted-by":"crossref","unstructured":"Yin LX, Reh DD, Hoag JB, Mitchell SE, Mathai SC, Robinson GM, Merlo CA. The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia. Laryngoscope. 2015; n\/a-n\/a.","DOI":"10.1002\/lary.25669"},{"issue":"1","key":"1453_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12955-017-0586-z","volume":"15","author":"R Zarrabeitia","year":"2017","unstructured":"Zarrabeitia R, Farinas-Alvarez C, Santibanez M, Senaris B, Fontalba A, Botella LM, Parra JA. Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT). Health Qual Life Outcomes. 2017;15(1):19.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"1453_CR29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ajmg.a.31101","volume":"140","author":"P Bayrak-Toydemir","year":"2006","unstructured":"Bayrak-Toydemir P, McDonald J, Markewitz B, Lewin S, Miller F, Chou LS, Gedge F, Tang W, Coon H, Mao R. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations. Am J Med Genet A. 2006;140(5):463\u201370.","journal-title":"Am J Med Genet A"},{"issue":"5","key":"1453_CR30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3174\/ajnr.A4210","volume":"36","author":"T Krings","year":"2015","unstructured":"Krings T, Kim H, Power S, Nelson J, Faughnan ME, Young WL, KG tB. Brain vascular malformation consortium HHTIG: neurovascular manifestations in hereditary hemorrhagic telangiectasia: imaging features and genotype-phenotype correlations. AJNR Am J Neuroradiol. 2015;36(5):863\u201370.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"1453_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13023-020-1337-5","volume":"15","author":"JM Mora-Lujan","year":"2020","unstructured":"Mora-Lujan JM, Iriarte A, Alba E, Sanchez-Corral MA, Cerda P, Cruellas F, Ordi Q, Corbella X, Ribas J, Castellote J, et al. Gender differences in hereditary hemorrhagic telangiectasia severity. Orphanet J Rare Dis. 2020;15(1):63.","journal-title":"Orphanet J Rare Dis"},{"key":"1453_CR32","doi-asserted-by":"crossref","unstructured":"Mora-Lujan JM, Iriarte A, Alba E, Sanchez-Corral MA, Berrozpe A, Cerda P, Cruellas F, Ribas J, Castellote J, Riera-Mestre A. Gastrointestinal Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia: Risk Factors and Endoscopic Findings. J Clin Med. 2019;9(82):1\u201313. (Epub ahead of print).","DOI":"10.3390\/jcm9010082"},{"issue":"4","key":"1453_CR33","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/lary.25604","volume":"126","author":"BN Hunter","year":"2016","unstructured":"Hunter BN, Timmins BH, McDonald J, Whitehead KJ, Ward PD, Wilson KF. An evaluation of the severity and progression of epistaxis in hereditary hemorrhagic telangiectasia 1 versus hereditary hemorrhagic telangiectasia 2. Laryngoscope. 2016;126(4):786\u201390.","journal-title":"Laryngoscope"},{"issue":"4","key":"1453_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1136\/jmg.2005.035451","volume":"43","author":"TG Letteboer","year":"2006","unstructured":"Letteboer TG, Mager JJ, Snijder RJ, Koeleman BP, Lindhout D, Ploos van Amstel JK, Westermann CJ. Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia. J Med Genet. 2006;43(4):371\u20137.","journal-title":"J Med Genet"},{"key":"1453_CR35","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/ncomms1633","volume":"3","author":"M Benzinou","year":"2012","unstructured":"Benzinou M, Clermont FF, Letteboer TG, Kim JH, Espejel S, Harradine KA, Arbelaez J, Luu MT, Roy R, Quigley D, et al. Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun. 2012;3:616.","journal-title":"Nat Commun"},{"key":"1453_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fgene.2015.00067","volume":"6","author":"TG Letteboer","year":"2015","unstructured":"Letteboer TG, Benzinou M, Merrick CB, Quigley DA, Zhau K, Kim IJ, Minh DT, Jablons DM, van Amstel JK, Westermann CJ, et al. Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14. Front Genet. 2015;6:67.","journal-title":"Front Genet"},{"issue":"7","key":"1453_CR37","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00270-017-1604-6","volume":"40","author":"JFB Chick","year":"2017","unstructured":"Chick JFB, Reddy SN, Pyeritz RE, Trerotola SO. A survey of pulmonary Arteriovenous malformation screening, management, and follow-up in hereditary hemorrhagic telangiectasia centers of excellence. Cardiovasc Intervent Radiol. 2017;40(7):1003\u20139.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"1453_CR38","first-page":"1031","volume":"98","author":"CL Shovlin","year":"2007","unstructured":"Shovlin CL, Sulaiman NL, Govani FS, Jackson JE, Begbie ME. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost. 2007;98(5):1031\u20139.","journal-title":"Thromb Haemost"},{"issue":"4","key":"1453_CR39","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/thoraxjnl-2011-201076","volume":"67","author":"JA Livesey","year":"2012","unstructured":"Livesey JA, Manning RA, Meek JH, Jackson JE, Kulinskaya E, Laffan MA, Shovlin CL. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli\/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax. 2012;67(4):328\u201333.","journal-title":"Thorax"},{"issue":"1","key":"1453_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13023-019-1172-8","volume":"14","author":"A Riera-Mestre","year":"2019","unstructured":"Riera-Mestre A, Mora-Lujan JM, Trujillo-Santos J, Del Toro J, Nieto JA, Pedrajas JM, Lopez-Reyes R, Soler S, Ballaz A, Cerda P, et al. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry. Orphanet J Rare Dis. 2019;14(1):196.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01453-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01453-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01453-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:11:00Z","timestamp":1626135060000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01453-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01453-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"9 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of North Carolina IRB approval was obtained to retrospectively review the medical records of adult patients with possible HHT who were evaluated at UNC HHT Clinic between January 1, 2009 to February 28, 2015.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}